-
EYPT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
EyePoint Pharmaceuticals (EYPT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm | 79.98 mm |
Cash burn (monthly) | 3.65 mm | 4.43 mm | 10.92 mm | 9.75 mm | 13.01 mm | 9.46 mm |
Cash used (since last report) | 18.53 mm | 22.53 mm | 55.47 mm | 49.53 mm | 66.10 mm | 48.06 mm |
Cash remaining | 61.45 mm | 57.45 mm | 24.51 mm | 30.45 mm | 13.88 mm | 31.92 mm |
Runway (months of cash) | 16.9 | 13.0 | 2.2 | 3.1 | 1.1 | 3.4 |
13F holders | Current |
---|---|
Total holders | 148 |
Opened positions | 29 |
Closed positions | 22 |
Increased positions | 68 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 532.29 bn |
Total shares | 88.79 mm |
Total puts | 224.80 k |
Total calls | 187.30 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 8.32 mm | $62.02 bn |
Suvretta Capital Management | 6.78 mm | $50.53 bn |
Adage Capital Partners GP, L.L.C. | 5.75 mm | $42.84 bn |
Adage Capital Management | 5.75 mm | $46.29 mm |
BlackRock | 5.28 mm | $39.35 bn |
BEN Franklin Resources | 4.14 mm | $30.82 bn |
Vanguard | 3.80 mm | $28.33 bn |
FHI Federated Hermes | 3.71 mm | $27.62 bn |
TCG Crossover Management | 3.57 mm | $26.61 bn |
TCG Crossover GP II | 3.57 mm | $41.40 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 25 | George Elston | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,834 | 0.00 | 75,550 |
9 Feb 25 | George Elston | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,834 | 0.00 | 0 |
9 Feb 25 | Nancy Lurker | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,000 | 0.00 | 205,436 |
9 Feb 25 | Nancy Lurker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 20,000 | 0.00 | 0 |
9 Feb 25 | Jay S. Duker | Common Stock | Payment of exercise | Dispose F | No | No | 6.495 | 2,055 | 13.35 k | 77,651 |
9 Feb 25 | Jay S. Duker | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,000 | 0.00 | 79,706 |
9 Feb 25 | Jay S. Duker | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,000 | 0.00 | 0 |
8 Jan 25 | Reginald J. Sanders | Stock Options Common Stock | Grant | Acquire A | No | No | 9.11 | 80,000 | 728.80 k | 80,000 |